0001209191-20-040670.txt : 20200702 0001209191-20-040670.hdr.sgml : 20200702 20200702185442 ACCESSION NUMBER: 0001209191-20-040670 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200623 FILED AS OF DATE: 20200702 DATE AS OF CHANGE: 20200702 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kihara James CENTRAL INDEX KEY: 0001816160 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 201011501 MAIL ADDRESS: STREET 1: C/O ACADIA PHARMACEUTICALS INC. STREET 2: 3611 VALLEY CENTRE DRIVE, SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3611 VALLEY CENTRE DRIVE STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 3611 VALLEY CENTRE DRIVE STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-06-23 0 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001816160 Kihara James C/O ACADIA PHARMACEUTICALS, INC. 3611 VALLEY CENTRE DRIVE, SUITE 300 SAN DIEGO CA 92130 0 1 0 0 Principal Accounting Officer Employee Stock Option (Right to Buy) 41.71 2030-04-06 Common Stock 32302 D Restricted Stock Units Common Stock 5955 D 25% of the shares subject to the Stock Option vest and become exercisable on April 7, 2021, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter. 50% of the restricted stock units vest on April 7, 2022 and 25% vest on each of April 7, 2023 and April 7, 2024. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. /s/ James K. Kihara 2020-07-02 EX-24.3_926451 2 poa.txt POA DOCUMENT POWER OF ATTORNEY Know all by these presents, that the undersigned hereby authorizes each of Austin D. Kim and/or Martin Choy to execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of ACADIA Pharmaceuticals Inc. (the "Company"), Forms 3, 4 and 5 and any Amendments thereto, and cause such form(s) to be filed with the Securities and Exchange Commission pursuant to Section 16(a) of the Securities Exchange Act of 1934, relating to the undersigned's beneficial ownership of securities in the Company. The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or substitute or substitutes of such attorney-in-fact, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 2nd day of July, 2020. /s/ James K. Kihara